Learn about Research & Clinical Trials
Safety and Efficacy of Faecal Microbiota Transplantation in Treatment-naïve Patients With Newly Diagnosed Chronic Inflammatory Diseases
The main purposes are to explore clinical efficacy aspects, safety, and patient acceptability associated with capsule faecal microbiota transplantation (cFMT) performed in newly diagnosed, untreated patients with chronic inflammatory rheumatic-, dermatological-, gastrointestinal- and pulmonary diseases. In this double-blind, placebo-controlled, randomised, 52-week exploratory trial, 200 patients with 10 different diagnoses of CIDs (n = 20 in each diagnosis stratum) fulfilling the study criteria will be enrolled at time of diagnosis. The baseline visit will be performed as quickly as possible (days) after the patient's informed...
Skeletal Muscle Function in Interstitial Lung Disease
Dyspnea (i.e. breathlessness) and exercise intolerance are common symptoms for patients with interstitial lung disease (ILD), yet it is not known why. It has been suggested that muscle dysfunction may contribute to dyspnea and exercise intolerance in ILD. Our study aims to: i) examine differences in the structure and function of the leg muscles in ILD patients, ii) determine if leg muscle fatigue contributes to dyspnea and exercise limitation in patients with ILD, and iii) determine the effects of breathing extra oxygen on leg muscle fatigue, as well as ability to exercise in ILD patients.
Soluble Programmed Death 1 (sPD1) is a Diagnostic Biomarker of ILD in Patients With Rheumatoid Arthritis Disease
1. Evaluate the levels of serum (sPD1) in RA patients with ILD and those without. 2. Detect subclinical RA-ILD for early diagnosis and management of this devastating manifestation of RA
Sputum Cytometry Guided Management for the Elimination of Chronic Cough in Patients With ILD
In Interstitial Lung Disease (ILD) there is thickening of lung tissue, which makes it difficult for patients to breathe and get enough oxygen into their bodies. In addition to shortness of breath, daily cough is very common, with 4 out of 5 patients experiencing this symptom. Cough in particular has a major impact on the ability to exercise, be active, and to simply enjoy life. There are many reasons for cough in ILD, and very often there are multiple overlapping causes. It is hard to improve cough in these patients, with available medicines providing limited relief. One explanation for this gap is an incomplete understanding of...
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
This interventional study will test whether a low cost and largely non-toxic small molecule, purified from green tea, EGCG, is safe when given to IPF patients with mild-moderate disease and without significant interactions with standard of care drugs. The rationale for the study is, first, the extensive prior pre-clinical data in mice that the trihydroxyphenolic EGCG is efficacious in attenuating pulmonary fibrosis by blocking collagen cross-linking and the pro-fibrotic pathway mediated by TGFβ1 signaling. More compelling are recently published data demonstrating that in humans EGCG is safe and capable of blocking lung tissue pro-fibrotic ...
Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
The purpose of this study is to identify the most promising therapeutic strategy for patients with granulomatosis with polyangiitis and inadequate response to standard of care therapy. It will evaluate the efficacy to induce remission of three different salvage strategies including: a combination of rituximab with addition of a conventional disease-modifying antirheumatic drugs (either methotrexate, azathioprine or mycophenolate mofetil, but preferentially methotrexate); tocilizumab; or abatacept.
Study of Single and Multiple Doses of PRS-220 Administered by Oral Inhalation in Healthy Subjects
A dose escalating study of PRS-220 administered by oral inhalation in healthy subjects
Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers
The trial was designed as a single-center, randomized, double-blind, single-dose parallel controlled phase I study to evaluate the similarity of pharmacokinetics and safety of Meperizumab injection and NUCALA® in healthy male volunteers. The plan is to enroll 88 healthy subjects. After signing the written informed consent voluntarily, the subjects will undergo a series of examinations and information collection to determine whether they meet the inclusion criteria. The qualified subjects will be randomized and administered. Biological samples were collected and safety checked before and after administration according to protocol...
Study Testing Convalescent Plasma vs Best Supportive Care
Currently there are no proven treatment option for COVID-19. Human convalescent plasma is an option for COVID-19 treatment and could be available from people who have recovered and can donate plasma.
Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis
The purpose of this study is to assess safety and tolerability of once daily (QD) and twice daily (BID) dosing of ANG-3070 in subjects with idiopathic pulmonary fibrosis (IPF) who are treatment-naïve, refused therapy, or discontinued for any reason current standard of care with nintedanib or pirfenidone.